Initial Treatment for Evans Syndrome

Diagnostic Evaluation

A complete blood count with differential, peripheral smear, and reticulocyte count should be performed to evaluate patients with Evans syndrome, according to the American Society of Clinical Oncology 3
A direct antiglobulin test (DAT) should be conducted to confirm the autoimmune hemolytic anemia component in patients with Evans syndrome, as recommended by the American Society of Clinical Oncology 3
Testing for underlying conditions, including viral infections (HIV, HCV, HBV, CMV) and Helicobacter pylori, should be performed in patients with Evans syndrome, as suggested by the American Society of Hematology 1, 3
Evaluation for lymphoproliferative disorders and autoimmune disorders (systemic lupus erythematosus, antiphospholipid syndrome) should be considered in patients with Evans syndrome, according to the American Society of Hematology 2, 3, 4

The American Society of Clinical Oncology recommends prednisone 1-2 mg/kg/day orally as the standard initial therapy for patients with Evans syndrome 3, 5, 6
The treatment should be continued until the platelet count increases (30-50 × 10^9/L), which may take several days to weeks, as suggested by the American Society of Hematology 5, 6
Once response is achieved, the prednisone dose should be tapered gradually over 4-6 weeks to the lowest effective dose, according to the American Society of Clinical Oncology 3
High-dose dexamethasone (40 mg/day for 4 days) may be considered as an alternative corticosteroid regimen, which can produce sustained responses in up to 50% of patients, as reported by the American Society of Hematology 5, 6

The American Society of Hematology recommends adding IVIg to corticosteroids when a more rapid increase in platelet count is required in patients with Evans syndrome 8, 9
The initial dose of IVIg should be 1 g/kg as a one-time dose, which may be repeated if necessary, as suggested by the American Society of Hematology 8, 9

Response to treatment should be evaluated based on platelet count improvement (goal >30 × 10^9/L and at least 2-fold increase from baseline), as recommended by the American Society of Hematology 2, 4
The absence of bleeding and resolution of hemolysis (improved hemoglobin, decreased reticulocyte count, normalized bilirubin) should also be assessed, according to the American Society of Hematology 2, 4